Trial reportCNS neuroscience & therapeutics2019
Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double-blind, placebo-controlled cross-over trial.
Trial report in CNS neuroscience & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double-blind, placebo-controlled cross-over trial.CNS neuroscience & therapeutics · 2019Trial
- Training effects in oculography in multiple sclerosis patients: a one-year longitudinal study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Article
- Identifying Biomarkers for Remyelination and Recovery in Multiple Sclerosis: A Measure of Progress.Biomedicines · 2025Review
- Measuring and predicting the effect of remyelinating therapy in multiple sclerosis: a randomised controlled trial protocol (RESTORE).BMJ open · 2024Article
- Visual outcome measures in clinical trials of remyelinating drugs.BMJ neurology open · 2024Review
- A novel eye-movement impairment in multiple sclerosis indicating widespread cortical damage.Brain : a journal of neurology · 2023Article
- Prolonged-release fampridine for the treatment of myoclonus after cervical myelitis: a case report.Therapeutic advances in neurological disorders · 2022Article
- A model for interrogating the clinico-radiological paradox in multiple sclerosis: Internuclear ophthalmoplegia.European journal of neurology · 2021Article
- Promoting remyelination in multiple sclerosis.Journal of neurology · 2021Review
- Diagnosing and quantifying a common deficit in multiple sclerosis: Internuclear ophthalmoplegia.Neurology · 2019Observational
- Ocular-motor conduction dynamics and variability in multiple sclerosis-related internuclear ophthalmoparesis: A randomized dalfampridine trial.Multiple sclerosis journal - experimental, translational and clinicalArticle
- Movement Disorder in Demyelinating Disease: Tracing the Charcot's Foot Print.Annals of Indian Academy of NeurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 3 countries.
Funding
Abstract
aimTo examine whether the velocity of saccadic eye movements in internuclear ophthalmoparesis (INO) improves with fampridine treatment in patients with multiple sclerosis (MS).
methodsRandomized, double-blind, placebo-controlled, cross-over trial with fampridine in patients with MS and INO. Horizontal saccades were recorded at baseline and at multiple time points post-dose. Main outcome measures were the change of peak velocity versional dysconjugacy index (PV-VDI) and first-pass amplitude VDI (FPA-VDI). Both parameters were compared between fampridine and placebo using a mixed model analysis of variance taking patients as their own control. Pharmacokinetics was determined by serial blood sampling.
resultsThirteen patients had a bilateral and 10 had a unilateral INO. One patient had an INO of abduction (posterior INO of Lutz) and was excluded. Fampridine significantly reduced both PV-VDI (-17.4%, 95% CI: -22.4%, -12.1%; P < 0.0001) and FPA-VDI (-12.5%, 95% CI: -18.9%, -5.5%; P < 0.01). Pharmacokinetics demonstrated that testing coincided with the average t
conclusionFampridine improves saccadic eye movements due to INO in MS. Treatment response to fampridine may gauge patient selection for inclusion to remyelination strategies in MS using saccadic eye movements as primary outcome measure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.